A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

Abstract Background Expressed on activated T and natural killer cells, 4-1BB/CD137 is a costimulatory receptor that signals a series of events resulting in cytokine secretion and enhanced effector function. Targeting 4-1BB/CD137 with agonist antibodies has been associated with tumor reduction and an...

Full description

Bibliographic Details
Main Authors: Ezra E. W. Cohen, Michael J. Pishvaian, Dale R. Shepard, Ding Wang, Jared Weiss, Melissa L. Johnson, Christine H. Chung, Ying Chen, Bo Huang, Craig B. Davis, Francesca Toffalorio, Aron Thall, Steven F. Powell
Format: Article
Language:English
Published: BMJ Publishing Group 2019-12-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
4-1BB
CD137
Utomilumab
Mogamulizumab
Solid tumors
Online Access:http://link.springer.com/article/10.1186/s40425-019-0815-6

Internet

http://link.springer.com/article/10.1186/s40425-019-0815-6

Similar Items